Literature DB >> 31559910

Cognitive decline on the Repeatable Battery for the Assessment of Neuropsychological Status in progressive supranuclear palsy.

Kevin Duff1, Christopher Randolph2, Adam L Boxer3.   

Abstract

Objective: Progressive supranuclear palsy (PSP) is associated with a variety of cognitive deficits, but few studies have reported on its cognitive trajectory across time, especially on the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
Methods: Two hundred twenty participants diagnosed with Richardson's syndrome of PSP (PSP-RS) were evaluated with the RBANS at baseline, six months, and one year with alternate forms.
Results: When using dependent t-tests, significant declines were observed on all Indexes of the RBANS from baseline to six months (ps < 0.01). Between six months and one year, significant declines were observed on three Indexes of the RBANS (ps < 0.05). Using existing regression-based change formulae from cognitively intact older adults, these participants with PSP showed significant decline on all RBANS Indexes (ps < 0.01) across one year. Finally, new regression-based change formulae were developed on this sample of individuals with PSP-RS to more precisely evaluate cognitive change in this condition.
Conclusion: In this large, longitudinal cohort of participants with PSP-RS, many (but not all) showed notable cognitive decline across six months and one year on the RBANS. The different methods of examining change across time yielded different results, with regression-based methods appearing to more accurately capture decline in this sample. These findings are expected to allow clinicians to more accurately evaluate cognitive trajectories in patients with PSP, as well as make better estimates of prognosis and offer more appropriate treatment recommendations. Such findings are also expected to inform clinical trials as to the changes in cognitive outcomes with this neurological condition.

Entities:  

Keywords:  Progressive supranuclear palsy; RBABS; cognitive change

Mesh:

Year:  2019        PMID: 31559910      PMCID: PMC7083686          DOI: 10.1080/13854046.2019.1670865

Source DB:  PubMed          Journal:  Clin Neuropsychol        ISSN: 1385-4046            Impact factor:   3.535


  32 in total

1.  Test-retest stability and practice effects of the RBANS in a community dwelling elderly sample.

Authors:  Kevin Duff; Leigh J Beglinger; Mike R Schoenberg; Doyle E Patton; James Mold; James G Scott; Russell L Adams
Journal:  J Clin Exp Neuropsychol       Date:  2005-07       Impact factor: 2.475

2.  Normative data for the repeatable battery for the assessment of neuropsychological status in elderly Chinese.

Authors:  Simon Lowes Collinson; Sam Hui Fang; May-Li Lim; Lei Feng; Tze-Pin Ng
Journal:  Arch Clin Neuropsychol       Date:  2014-06-05       Impact factor: 2.813

3.  A clinical rating scale for progressive supranuclear palsy.

Authors:  Lawrence I Golbe; Pamela A Ohman-Strickland
Journal:  Brain       Date:  2007-04-02       Impact factor: 13.501

4.  Neuropsychological follow up in patients with Parkinson's disease, striatonigral degeneration-type multisystem atrophy, and progressive supranuclear palsy.

Authors:  P Soliveri; D Monza; D Paridi; F Carella; S Genitrini; D Testa; F Girotti
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-09       Impact factor: 10.154

5.  The role of cognitive impairment in general functioning in major depression.

Authors:  Bernhard T Baune; Robyn Miller; Jordan McAfoose; Melissa Johnson; Frances Quirk; David Mitchell
Journal:  Psychiatry Res       Date:  2010-04-30       Impact factor: 3.222

6.  Practice effects during repeated administrations of memory tests with and without alternate forms.

Authors:  R H Benedict; D J Zgaljardic
Journal:  J Clin Exp Neuropsychol       Date:  1998-06       Impact factor: 2.475

Review 7.  Clinical and genetic aspects of progressive supranuclear palsy.

Authors:  I Litvan; M Hutton
Journal:  J Geriatr Psychiatry Neurol       Date:  1998       Impact factor: 2.680

8.  Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.

Authors:  Adam L Boxer; Anthony E Lang; Murray Grossman; David S Knopman; Bruce L Miller; Lon S Schneider; Rachelle S Doody; Andrew Lees; Lawrence I Golbe; David R Williams; Jean-Cristophe Corvol; Albert Ludolph; David Burn; Stefan Lorenzl; Irene Litvan; Erik D Roberson; Günter U Höglinger; Mary Koestler; Clifford R Jack; Viviana Van Deerlin; Christopher Randolph; Iryna V Lobach; Hilary W Heuer; Illana Gozes; Lesley Parker; Steve Whitaker; Joe Hirman; Alistair J Stewart; Michael Gold; Bruce H Morimoto
Journal:  Lancet Neurol       Date:  2014-05-27       Impact factor: 44.182

9.  Executive dysfunction is the primary cognitive impairment in progressive supranuclear palsy.

Authors:  Adam Gerstenecker; Benjamin Mast; Kevin Duff; Tanis J Ferman; Irene Litvan
Journal:  Arch Clin Neuropsychol       Date:  2012-11-04       Impact factor: 2.813

10.  Behavioral abnormalities in progressive supranuclear palsy.

Authors:  Adam Gerstenecker; Kevin Duff; Benjamin Mast; Irene Litvan
Journal:  Psychiatry Res       Date:  2013-09-12       Impact factor: 3.222

View more
  1 in total

1.  Cognitive and behavioral profile of progressive supranuclear palsy and its phenotypes.

Authors:  Andrea Horta-Barba; Javier Pagonabarraga; Saül Martínez-Horta; Laura Busteed; Berta Pascual-Sedano; Ignacio Illán-Gala; Juan Marin-Lahoz; Ignacio Aracil-Bolaños; Jesús Pérez-Pérez; Frederic Sampedro; Helena Bejr-Kasem; Jaime Kulisevsky
Journal:  J Neurol       Date:  2021-03-11       Impact factor: 4.849

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.